文献速递肝病

失代偿期肝硬化患者血小板聚集增强提示进一步失代偿和死亡风险更高

Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death.
PubMed 文献 · J Hepatol · 2022-03-29

前瞻性研究纳入203例肝硬化患者(77%失代偿),以全血聚集法计算血小板聚集与血小板计数比值(PLT比值),发现肝硬化患者PLT比值显著高于慢性肝炎及健康人,且随病情加重而升高;PLT比值>0.75者6个月内进一步失代偿、移植或死亡风险为PLT比值<0.25者的7.5倍。

要点

  • 肝硬化患者全血血小板聚集与血小板计数的比值显著高于健康人。
  • 失代偿期肝硬化中PLT比值随Child-Pugh分级升高而增高。
  • PLT比值>0.75的失代偿患者6个月内发生进一步失代偿、移植或肝病死亡的概率>80%。

核心结论

  • 肝硬化尤其失代偿期患者全血血小板聚集显著增强。
  • 失代偿患者PLT比值>0.75者6个月内进一步失代偿、移植或肝病死亡概率>80%。

研究设计与样本

  • 前瞻性研究,纳入203例肝硬化患者(77%失代偿),以全血聚集法(Multiplate®)评估血小板聚集并计算PLT比值。
  • 另在41例住院失代偿期肝硬化患者独立队列中验证。

主要发现

  • 肝硬化患者PLT比值为0.44,高于慢性肝炎患者的0.25和健康人的0.26(p<0.0001)。
  • 肝硬化患者PLT比值随Child-Pugh分级升高而增加(C级>B级>A级),在严重血小板减少的失代偿患者中尤其升高。
  • 失代偿患者中65例在6个月随访内发生进一步失代偿、接受移植或死亡。
  • 多因素分析显示PLT比值(比值比1.87;95%CI 1.23-2.84;p=0.003)与MELD评分(比值比1.05;95%CI 1.01-1.08;p=0.01)与结局独立相关。
  • PLT比值>0.75者发生事件的相对风险为PLT比值<0.25者的7.5倍(95%CI 2.5-21.9;p=0.003)。

关键数值与推荐

  • PLT比值>0.75 vs PLT比值<0.25:事件相对风险7.5倍(95%CI 2.5-21.9;p=0.003)。
  • PLT比值每单位:比值比1.87(95%CI 1.23-2.84;p=0.003)。
  • MELD评分每分:比值比1.05(95%CI 1.01-1.08;p=0.01)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Studies on platelet aggregation in cirrhosis are controversial because interpretation of platelet function is challenged by thrombocytopenia. We conducted a prospective study to investigate whole blood platelet aggregation in cirrhosis and its association with liver-related outcomes. METHODS: Platelet aggregation was assessed by whole blood aggregometry (Multiplate®). To overcome the influence of platelet count and compare cirrhosis with thrombocytopenia vs. controls with normal platelet count, we calculated a ratio between platelet aggregation and platelet count (PLT ratio). Then, we prospectively followed patients with cirrhosis and ascertained predictors of decompensation, transplantation, and death. RESULTS: Two-hundred and three patients with cirrhosis were prospectively recruited (77% decompensated). PLT ratio was significantly higher in cirrhosis than in those with chronic hepatitis and healthy individuals (0.44 vs. 0.25 and 0.26, respectively; p <0.0001). In cirrhosis, the ratio increased with disease severity (Child-Pugh class C>B>A) and was particularly elevated in decompensated patients with severe thrombocytopenia. Among decompensated patients, 65 had further decompensation, underwent transplantation, or died during a 6-month follow-up. On multivariate analysis, PLT ratio (odds ratio 1.87; 95% CI 1.23-2.84; p = 0.003) and MELD score (odds ratio 1.05; 95% CI 1.01-1.08; p = 0.01) were independently associated with outcome. The relative risk of events was 7.5-fold higher in patients with PLT ratio >0.75 vs. patients with PLT ratio <0.25 (95% CI 2.5-21.9; p = 0.003). The increased PLT ratio, its discriminative ability for composite outcome, and the prognostic value of PLT ratio >0.75 were confirmed in an independent cohort of hospitalized patients with decompensated cirrhosis (n = 41). CONCLUSIONS: Patients with cirrhosis, particularly when decompensated, exhibit significantly increased whole blood platelet aggregation. Decompensated patients with a PLT ratio >0.75 have a >80% probability of further decompensation, transplantation, or liver-related death within 6 months. LAY SUMMARY: In patients with cirrhosis, previous studies have suggested that platelets (i.e. circulating blood cells that help form clots to stop bleeding) are dysfunctional. In particular, these studies suggested that platelet aggregation (the process by which platelets adhere to each other to form clots) is reduced. Since platelet aggregation is important for clot formation, it has been hypothesized that alterations of platelet aggregation may be responsible for the increased risk of bleeding observed in patients with cirrhosis. Our study demonstrates: i) that platelet aggregation in patients with cirrhosis is higher than in healthy individuals; ii) that platelet aggregation in patients with decompensated cirrhosis (i.e. those who have already experienced some complications of cirrhosis) is particularly elevated and associated with risk of further complications and death.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Zanetto A, Campello E, Bulato C, et al. Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death. J Hepatol. 2022. PMID: 35364225. doi:10.1016/j.jhep.2022.03.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。